Tumour Markers for MRCP Part 1
- Crack Medicine
- 1 day ago
- 5 min read
TL;DR
Tumor Markers (CA-125, CA19-9, CEA) are frequently tested in MRCP Part 1, particularly regarding their clinical indications, limitations, and interpretation. Candidates should remember that these markers are not suitable as general cancer screening tests and are mainly used alongside clinical assessment and imaging for diagnosis, prognosis, or monitoring treatment response. Understanding common examination pitfalls is far more valuable than memorising isolated associations.
Why this matters
Tumour markers regularly appear in MRCP Part 1 because they test both factual recall and clinical reasoning. Rather than asking for simple memorisation, examination questions often assess whether candidates understand:
when a marker should be requested,
what it actually measures,
its diagnostic limitations,
common causes of false-positive results,
and how it influences patient management.
Many candidates lose marks by assuming that a raised tumour marker automatically confirms malignancy. In reality, tumour markers have limited sensitivity and specificity and must always be interpreted within the clinical context.
For a broader revision strategy, see the MRCP Part 1 overview:https://www.crackmedicine.com/mrcp-part-1/
Core sections
Scope of tumour markers in clinical practice
Tumour markers are substances produced by tumour cells or by normal tissues in response to malignancy. They may be detected in blood, urine or body fluids.
Their principal uses include:
Monitoring treatment response
Detecting disease recurrence
Supporting diagnosis alongside imaging
Estimating prognosis
Occasionally helping identify the tissue of origin
They are rarely appropriate for population screening, largely because of poor specificity.
The five most tested subtopics
1. CA-125
CA-125 is a glycoprotein produced by tissues derived from the coelomic epithelium.
Most commonly associated with:
Epithelial ovarian carcinoma
However, MRCP questions frequently emphasise that elevated CA-125 is not specific for ovarian cancer.
Common benign causes include:
Endometriosis
Menstruation
Pregnancy
Pelvic inflammatory disease
Liver cirrhosis
Heart failure
Peritoneal inflammation
High-yield facts:
Useful for monitoring treatment response.
Useful for detecting recurrence.
Not suitable for screening asymptomatic women.
Can be elevated in many inflammatory conditions.
2. CA19-9
CA19-9 is the tumour marker classically associated with pancreatic malignancy.
Important associations:
Pancreatic adenocarcinoma
Cholangiocarcinoma
Gastric carcinoma
Colorectal carcinoma
Important limitations:
Benign elevations occur with:
Acute pancreatitis
Chronic pancreatitis
Biliary obstruction
Cholangitis
Liver disease
An important MRCP fact:
Approximately 5–10% of individuals who are Lewis antigen negative cannot produce CA19-9, even when advanced pancreatic cancer is present.
3. CEA (Carcinoembryonic Antigen)
CEA is primarily associated with colorectal cancer.
Clinical uses:
Monitoring after colorectal cancer surgery
Detecting recurrence
Assessing metastatic disease
CEA may also be elevated in:
Gastric cancer
Pancreatic cancer
Breast cancer
Lung cancer
False-positive elevations occur in:
Cigarette smokers
Liver disease
Inflammatory bowel disease
Pancreatitis
COPD
Therefore, CEA should never be interpreted in isolation.
4. Clinical interpretation
A tumour marker result should always answer one of three questions:
Does it support the suspected diagnosis?
Can it monitor treatment?
Can it detect recurrence?
If the answer is "none of these," ordering the test is often inappropriate.
This principle appears repeatedly in MRCP examination scenarios.
5. Limitations of tumour markers
No tumour marker possesses perfect sensitivity and specificity.
Limitations include:
False positives
False negatives
Variation between laboratories
Elevation in benign disease
Limited value in early-stage cancers
Candidates should remember that imaging and histopathology remain the diagnostic gold standards.
High-yield comparison table
Tumour marker | Common association | Major clinical use | Important benign causes of elevation |
CA-125 | Ovarian carcinoma | Monitoring treatment and recurrence | Endometriosis, menstruation, pregnancy, liver disease |
CA19-9 | Pancreatic carcinoma | Monitoring advanced disease | Biliary obstruction, pancreatitis, cholangitis |
CEA | Colorectal carcinoma | Detecting recurrence after surgery | Smoking, liver disease, inflammatory bowel disease |
10 high-yield examination points
Tumour markers are not diagnostic on their own.
CA-125 is primarily associated with epithelial ovarian cancer.
Endometriosis commonly causes raised CA-125.
CA19-9 is associated with pancreatic adenocarcinoma.
Obstructive jaundice can markedly elevate CA19-9.
Lewis antigen-negative individuals may have falsely low CA19-9.
CEA is mainly used to monitor colorectal cancer.
Smoking increases CEA.
Tumour markers are generally better for monitoring than diagnosis.
Histological confirmation is required before definitive cancer treatment.
Practical examples / mini-cases
Mini-case
A 67-year-old man underwent curative surgery for colorectal carcinoma one year ago. During routine follow-up, his CEA has progressively increased over three consecutive visits despite being asymptomatic.
What is the most appropriate next step?
A. Repeat CEA in two years
B. Begin chemotherapy immediately
C. Arrange imaging to investigate recurrence
D. Diagnose metastatic disease based on CEA alone
E. Ignore because smokers often have elevated CEA
Correct answer: C. Arrange imaging to investigate recurrence
Explanation
CEA is valuable for surveillance after colorectal cancer treatment. A rising trend raises suspicion for recurrent disease but does not confirm recurrence. Imaging such as CT scanning should be performed before making management decisions.
Practical study-tip checklist
✔ Learn the major cancer association for each marker.
✔ Memorise at least three benign causes of elevation.
✔ Know whether the marker is mainly used for diagnosis or monitoring.
✔ Remember that tumour markers are adjuncts—not definitive diagnostic tests.
✔ Revise common MRCP clinical scenarios rather than isolated facts.
✔ Practise interpretation questions using realistic clinical vignettes in the Free MRCP MCQs:https://www.crackmedicine.com/qbank/
✔ Reinforce knowledge with timed revision using:https://www.crackmedicine.com/mock-tests/
Common pitfalls (5 bullets)
Believing tumour markers are appropriate screening tests for healthy individuals.
Diagnosing cancer solely because a tumour marker is elevated.
Forgetting common benign causes of raised CA-125.
Missing the effect of obstructive jaundice on CA19-9.
Assuming a normal tumour marker excludes malignancy.
FAQs
Is CA-125 specific for ovarian cancer?
No. Although strongly associated with epithelial ovarian cancer, CA-125 also rises in several benign conditions including endometriosis, pregnancy, pelvic inflammatory disease and liver disease.
Why is CA19-9 not recommended for pancreatic cancer screening?
Its sensitivity and specificity are insufficient for screening. Benign biliary disease and pancreatitis frequently cause elevated values, while Lewis antigen-negative individuals may not produce CA19-9 at all.
What is the main clinical use of CEA?
CEA is primarily used to monitor patients after treatment for colorectal cancer and to detect disease recurrence during follow-up.
Can normal tumour markers exclude cancer?
No. Early-stage malignancy may produce normal marker levels. Clinical assessment, imaging and histopathology remain essential.
Which tumour marker is most commonly tested in MRCP Part 1?
CA-125, CA19-9 and CEA are the most frequently examined markers, especially in questions focusing on appropriate clinical use and interpretation rather than diagnosis alone.
Ready to start
Understanding tumour markers is far easier when studied alongside clinical scenarios rather than isolated facts. Continue your preparation with the MRCP Part 1 overview:
Then strengthen your recall using:
Free MRCP MCQs: https://www.crackmedicine.com/qbank/
Full-length practice exams: https://www.crackmedicine.com/mock-tests/
Comprehensive MRCP lectures: https://www.crackmedicine.com/lectures/
You may also find these related topics helpful:
Autoantibodies (Anti-Jo1, Anti-Ro, Anti-Scl70)
Drug Rashes: SJS vs TEN vs DRESS
Sources
MRCP(UK). Syllabus and Examination Blueprint. https://www.mrcpuk.org/
National Institute for Health and Care Excellence (NICE). Ovarian cancer: recognition and initial management. https://www.nice.org.uk/
European Society for Medical Oncology (ESMO). Clinical Practice Guidelines. https://www.esmo.org/guidelines
American Society of Clinical Oncology (ASCO). Tumour markers in oncology. https://www.asco.org/
National Cancer Institute. Tumor Markers Fact Sheet. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
Comments